The German firm said that researchers can now run its GynTect cervical cancer assay on Roche Diagnostics' Cobas z 480 analyzer.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The assay's CE marking permits its use for the early diagnosis of HIV-1 in infants and for measuring viral load and disease progression using dried blood spot samples.
The test combines qPCR and microarray technology to detect carbapenemase-producing enterobacteriaceae, a bacteria resistance to carbapenem antibiotics.
The newly launched RT-PCR-based molecular diagnostic kits are designed for use in monitoring post-transplantation and immunosuppressed patients.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
The firm’s test for detecting flu and differentiating between subtypes A and B is being launched in Europe, Asia, and South America.
By achieving certification for the assay, called PredictSure IBD, the Cambridge, UK-based firm can sell it for clinical use across Europe.
The firm's assay measures the concentration of the wild type and mutant alleles of hFE protein at three different mutation sites from a person's blood sample.
The firm said that the Resistance GC assay will allow doctors to treat up to 70 percent of infected patients with a single dose of ciprofloxacin.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.